Itopride in Functional Dyspepsia:a Dose Finding Study
Status:
Completed
Trial end date:
2002-01-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the
treatment of patients with functional dyspepsia.
The study will test in patients with functional dyspepsia the hypothesis that itopride is
superior to placebo with regard to the improvement of symptoms.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Royal Adelaide Hospital
Collaborators:
Knoll Pharmaceuticals, Germany (now Abbott) University Hospital, Essen